Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.

ABSTRACT:

Background

Metformin slows tumor growth and progression in vitro, and in combination with chemoradiotherapy, resulted in high overall survival in patients with head and neck cancer squamous cell carcinoma (HNSCC) in our phase 1 clinical trial (NCT02325401). Metformin is also postulated to activate an antitumor immune response. Here, we investigate immunologic effects of metformin on natural killer (NK) and natural killer T cells, including results from two phase I open-label studies in patients with HNSCC treated with metformin (NCT02325401, NCT02083692).

Methods

Peripheral blood was collected before and after metformin treatment or from newly diagnosed patients with HNSCC. Peripheral immune cell phenotypes were evaluated using flow cytometry, cytokine expression by ELISA an

SUBMITTER: Crist M 

PROVIDER: S-EPMC9639146 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature